MOTS-c: A Signal Encoded Inside the Mitochondrial Genome

The short version

MOTS-c is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR. What makes it unusual is where it comes from: it is encoded not in the nuclear genome but in the mitochondrial genome — specifically within a short open reading frame embedded inside the 12S ribosomal RNA gene (MT-RNR1). That makes it part of a small family called mitochondrial-derived peptides, or MDPs, which are thought to serve as stress-signals between the mitochondrion and the rest of the cell.

MOTS-c's best-characterized mechanism is activating AMPK, the cell's master energy-sensing kinase, by interfering with folate-cycle and purine-biosynthesis reactions — a somewhat indirect route. Under metabolic stress it translocates from the mitochondrion to the nucleus and regulates nuclear gene expression ^[12]. A 2021 Nature Communications study found that exogenous MOTS-c improved treadmill capacity, grip strength, and gait in aged mice (22-month-old, roughly analogous to older humans) ^[11].

Human evidence is observational: circulating MOTS-c was independently associated with mortality and cardiovascular outcomes in a cohort of chronic hemodialysis patients ^[9]. There are no human interventional trials. MOTS-c is a research chemical, not an approved drug, and is treated as a prohibited substance in sport. This page reports the science only; it lists no human dose.

What it is

MOTS-c is a 16-amino-acid linear peptide with the sequence Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg. It is encoded by a short open reading frame within the mitochondrial 12S rRNA gene (MT-RNR1) of the mitochondrial genome, and is highly conserved across mammalian species — a sign that its function has been maintained by natural selection.

It was first described as a mitochondrial-derived signaling peptide in 2015, and is the best-characterized member of the MDP family alongside another peptide called humanin. Because it is encoded by the mitochondrial genome, its expression is influenced by mitochondrial genotype; a pro-diabetogenic variant at the encoding locus (m.1382A>C) and ancestry-dependent differences in MOTS-c biology have been documented in human populations.

In the research context, MOTS-c is a synthetic peptide produced by solid-phase synthesis. It is sold as a research chemical for laboratory use only; it is not an approved drug or dietary supplement.

How it works

MOTS-c's primary mechanism begins inside the mitochondrion. It inhibits enzymes in the folate cycle and de-novo purine biosynthesis pathway, which raises intracellular levels of the metabolite AICAR (5-aminoimidazole-4-carboxamide ribonucleotide). AICAR is a known AMPK activator, so MOTS-c activates AMPK indirectly via this metabolic route. AMPK activation improves glucose uptake in skeletal muscle — the tissue most studied for MOTS-c — and underpins reported improvements in insulin sensitivity and metabolic flexibility.

Under metabolic stress, MOTS-c translocates from the mitochondrion to the nucleus. A 2018 Cell Metabolism study established that this nuclear translocation is AMPK-dependent and that MOTS-c subsequently regulates nuclear gene expression, including antioxidant-response-element (ARE) genes via interaction with the transcription factor NRF2 — the first demonstrated retrograde signaling from the mitochondrial genome to the nucleus by a mitochondrially encoded peptide ^[12].

A 2024 study in iScience added further mechanistic resolution: MOTS-c directly binds and activates casein kinase 2 (CK2) in cell-free assays. Tissue-specific CK2 modulation — activation in muscle, suppression in adipose tissue — was shown to underlie MOTS-c's effects on muscle glucose uptake and prevention of atrophy ^[8]. The picture that emerges is a peptide with multiple downstream effectors that converge on metabolic stress-adaptation.

What the research shows

Mechanism: nuclear retrograde signaling. MOTS-c translocates to the nucleus under metabolic stress and regulates ARE/antioxidant and metabolic genes in an AMPK-dependent manner, via interaction with NRF2 — the first mitochondrially encoded peptide shown to regulate nuclear gene expression ^[12].

Direct molecular target. MOTS-c binds and activates CK2 in a cell-free system; tissue-specific CK2 modulation prevents skeletal muscle atrophy and enhances muscle glucose uptake in young, aged, high-fat-diet, and immobilized mice ^[8].

Comprehensive mechanism review. A 2023 Journal of Translational Medicine review synthesized MOTS-c's MT-RNR1 encoding, AMPK/folate-cycle mechanism, nuclear-translocation behavior, exercise-inducibility, and roles in metabolic, stress-adaptive, and aging pathways — the standard orientation reference for the field ^[10].

Exercise mimetic in aged mice. Exercise induces endogenous MOTS-c expression in skeletal muscle and circulation. Exogenous MOTS-c significantly increased treadmill running capacity (p=0.000002), grip strength, and gait in 22-month-old mice; effects were seen across young (2-month), middle-aged (12-month), and old (22-23.5-month) animals, positioning MOTS-c as a candidate exercise-mimetic regulator of healthspan ^[11].

Human biomarker association. In a prospective multicenter cohort of 94 chronic hemodialysis patients followed for a median of 26.5 months, circulating MOTS-c was independently associated with a composite endpoint of all-cause mortality and non-fatal cardiovascular events. Adding MOTS-c to the risk model improved ROC AUC from 0.727 to 0.743 (Cox HR 1.004, p=0.05) — among the strongest human clinical-association data published for any MDP ^[9]. Note: this is an association study, not a controlled intervention.

Reported effects, cautions & safety

MOTS-c has no human interventional safety or efficacy trials. The cautions are specific and substantial:

• Entirely preclinical efficacy. Every claim about exogenous MOTS-c improving metabolism, exercise capacity, or aging comes from cell or animal studies (predominantly mice). Human data are observational biomarker associations, not interventional outcomes ^[10].
• No validated human pharmacokinetics. There is no published, measured human half-life, bioavailability, or dose-response for MOTS-c. Rodent doses used in published studies (0.5-15 mg/kg/day) cannot be extrapolated to humans.
• Anti-doping prohibition. MOTS-c is treated as a prohibited substance in elite sport by anti-doping bodies including USADA/WADA under hormone- and metabolic-modulator categories. Athlete use can result in sanctions.
• Research-chemical status. MOTS-c is sold only for laboratory research; product purity, identity, and sterility vary by supplier and are not regulated as pharmaceuticals.
• Population heterogeneity. A pro-diabetogenic mitochondrial DNA variant (m.1382A>C) and ancestry-dependent exercise responses to endogenous MOTS-c suggest effects are not uniform across individuals or populations.
• Marketplace claims outpace evidence. Consumer interest in MOTS-c for fat loss, longevity, and performance greatly exceeds the strength of available clinical evidence.

No community-anecdote reports are compiled in this desk's source material for MOTS-c, so none are presented; the cautions above are drawn from the cited literature.

Where it fits in longevity and cellular-energetics research

MOTS-c is the mitochondrial-signaling molecule on this desk — the one that demonstrates the mitochondrion is not merely a passive energy factory but an active signal-generator that communicates with the nucleus ^[12]. Where NAD+ approaches cellular aging through substrate replenishment — restoring the metabolic currency — MOTS-c approaches it through a signaling route that activates overlapping downstream targets (notably AMPK and NRF2) via a completely different mechanism. The two are thus complementary angles on mitochondrial health with aging.

MOTS-c has the more dramatically preliminary evidence base: a rich animal record, one human biomarker cohort, and zero interventional human trials. NAD+ precursors have human RCTs behind them but an unresolved gap between blood-level changes and clinical outcomes. Together they illustrate the field's common arc — strong preclinical signal, costly and slow translation to human benefit. See how they compare on the comparison page.